Visión generalGráficoNoticiasTraderScreen

HSBC WAR. CALL 03/25 TDXP/  DE000HS4FYC7  /

gettex Zettex2
14/11/2024  15:37:23 Diferencia-0.0010 Bid16:15:10 Ask16:15:10 Subyacente Precio de ejercicio Fecha de expiración Tipo de opción
0.0320EUR -3.03% 0.0340
Volumen de oferta: 10,000		 0.0840
Tamaño/ Volumen/ Formato de Ask: 10,000		 TECDAX 4,100.00 EUR 21/03/2025 Call
GlobeNewswire 22/07 MiddleGround Capital enters into Investment Agreement with STEMMER IMAGING AG and announces intentio...
GlobeNewswire 12/06/2018 Software AG acquires Technology Scale-up TrendMiner for analysis and visualization of time series da...
GlobeNewswire 20/12/2016 Medigene announces outlicensing of AAVLP technology
GlobeNewswire 13/12/2016 MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...
GlobeNewswire 06/12/2016 Medigene AG to be included in TecDAX Index
GlobeNewswire 06/12/2016 MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 201...
GlobeNewswire 06/12/2016 MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016
GlobeNewswire 28/11/2016 MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application Fo...
GlobeNewswire 17/11/2016 MorphoSys Announces That Its Licensee Janssen Has Submitted Biologics License Application For Guselk...
GlobeNewswire 15/11/2016 MorphoSys Raises EUR 115 million in Private Placement
GlobeNewswire 15/11/2016 Ad hoc: MorphoSys Raises EUR 115 million in Private Placement
GlobeNewswire 15/11/2016 MorphoSys to Raise Capital via a Private Placement of New Shares
GlobeNewswire 15/11/2016 Ad hoc: MorphoSys to Raise Capital via a Private Placement of New Shares
GlobeNewswire 15/11/2016 MorphoSys Announces That Its Licensee Janssen Has Presented Positive Clinical Data of Guselkumab in ...
GlobeNewswire 14/11/2016 MorphoSys to Present at Upcoming Investor Conferences
GlobeNewswire 08/11/2016 Anke Linnartz joins MorphoSys as Head of Corporate Communications and Investor Relations
GlobeNewswire 07/11/2016 MorphoSys AG Reports Results for the First Nine Months of 2016
GlobeNewswire 03/11/2016 MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) ...
GlobeNewswire 02/11/2016 MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatol...
GlobeNewswire 28/10/2016 MorphoSys to Host Q3 2016 Conference Call on November 7, 2016
GlobeNewswire 20/10/2016 MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody
GlobeNewswire 17/10/2016 MorphoSys Presents Updated Clinical Results for MOR202 at Medical Conference
GlobeNewswire 01/10/2016 MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Gusel...
GlobeNewswire 01/10/2016 Ad hoc: MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study ...
GlobeNewswire 29/09/2016 MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis